We are partnering with pharmaceutical and biotechnology companies to maximise the potential of the platform.
As a company we are flexible in our approach to collaboration. Our partnership models include:
Re-engineer We re-engineer our partner’s drug candidates to improve key properties.
Novel products We engineer known scaffolds to meet our partner’s product requirements.
Out-license We identify, launch and run internal drug development projects and out-license them to partners during pre-clinical development.
Tillotts Pharma AG X LabGenius
We are currently working with Tillotts Pharma AG to identify and develop new drug candidates for the treatment of inflammatory bowel disease (IBD). There is still a large unmet need for novel therapeutic approaches in IBD as many patients do not respond to the presently available drugs.